Literature DB >> 2541390

Depletion of PDGF from serum inhibits growth of AIDS-related and sporadic Kaposi's sarcoma cells in culture.

W K Roth1, S Werner, C G Schirren, P H Hofschneider.   

Abstract

We have examined the mitogenic potential of platelet-derived growth factor (PDGF) on AIDS (acquired immune deficiency syndrome)-related and sporadic Kaposi's sarcoma cells in comparison to fibroblasts at physiological and subphysiological calcium concentrations of the culture medium. At low calcium concentrations in the presence of 3% human serum the growth rate of fibroblasts and Kaposi's sarcoma (KS) cells is similarly reduced to less than half of the growth rate at physiological Ca2+ concentrations. In the presence of 3% PDGF depleted, platelet poor plasma-derived serum (PPPS) growth of KS cells ceased completely, whereas fibroblasts made 1-2 cell divisions within 15 days. At physiological Ca2+ concentrations, the reduced PDGF content in 3% PPPS had no effect on human embryonal fibroblasts and little effect on adult skin fibroblasts. In contrast, KS cells became growth-arrested after one to two doublings. This is consistent with the observation that PDGF B-chain mRNA could not be detected in our KS cells whereas PDGF receptor mRNA was expressed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541390

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  HIV-associated Kaposi's sarcoma: new developments in epidemiology and molecular pathology.

Authors:  W K Roth
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 2.  [Primary sarcomas and sarcoma metastases in the liver: morphological and molecular aspects].

Authors:  G Mechtersheimer; R Penzel; W J Hofmann; P Schirmacher
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

3.  Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma.

Authors:  E Cornali; C Zietz; R Benelli; W Weninger; L Masiello; G Breier; E Tschachler; A Albini; M Stürzl
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

4.  Consensus-interferon and platelet-derived growth factor adversely regulate proliferation and migration of Kaposi's sarcoma cells by control of c-myc expression.

Authors:  R Köster; L M Blatt; M Streubert; C Zietz; H Hermeking; W Brysch; M Stürzl
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

5.  Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells.

Authors:  J Corbeil; E Rapaport; D D Richman; D J Looney
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 6.  Kaposi's sarcoma in HIV infected women in Germany: more evidence for sexual transmission. A report of 10 cases and review of the literature.

Authors:  H Albrecht; E B Helm; A Plettenberg; C Emminger; W Heise; B Schwartländer; H J Stellbrink
Journal:  Genitourin Med       Date:  1994-12

7.  CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma.

Authors:  J Pammer; A Plettenberg; W Weninger; B Diller; M Mildner; A Uthman; W Issing; M Stürzl; E Tschachler
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

8.  Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance.

Authors:  M Stürzl; W K Roth; N H Brockmeyer; C Zietz; B Speiser; P H Hofschneider
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

Review 9.  Targeted therapy for Kaposi sarcoma.

Authors:  Ryan J Sullivan; Liron Pantanowitz; Bruce J Dezube
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

10.  Exploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infection.

Authors:  Myung-Shin Lee; Tiffany Jones; Dae-Yong Song; Jae-Hyuk Jang; Jae U Jung; Shou-Jiang Gao
Journal:  PLoS Pathog       Date:  2014-09-25       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.